15 September 2020 - Brenzys is a biosimilar biologic drug authorised based on its similarity to Enbrel, which is already approved for use in Canada.

Merck Canada announced today that Health Canada has approved Brenzys, a TNF-inhibitor, for four new indications:

• Adult patients with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy
• Paediatric patients ages 4 to 17 years with chronic severe psoriasis who are candidates for systemic therapy or phototherapy
• Reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis and improving physical function in adult patients with psoriatic arthritis
• Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients aged 4 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs

Read Merck press release